Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug
<a href="https://pixabay.com/users/stevepb/">stevepb</a> / Pixabay

Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug

  Takeda Pharmaceutical Company Limited and Ovid Therapeutics have released an overview of the clinical development program for TAK-935/OV935, an investigational drug that is being developed as a potential anti-epileptic…

Continue Reading
Close Menu